Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:CGTX NASDAQ:NRIX NASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.64+7.0%$3.43$2.70▼$4.62$891.40M1.01910,144 shs1.42 million shsCGTXCognition Therapeutics$2.49-1.6%$1.32$0.22▼$3.83$184.54M1.334.89 million shs1.82 million shsNRIXNurix Therapeutics$9.00-2.2%$10.87$8.18▼$29.56$689.57M2.1859,324 shs247,228 shsOCSOculis$17.15-0.2%$17.77$11.78▼$23.08$748.77M0.2642,405 shs12,823 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+5.87%+13.35%+27.35%+23.71%-3.56%CGTXCognition Therapeutics+5.42%+4.12%+235.32%+697.60%+318.53%NRIXNurix Therapeutics-5.15%+0.99%-6.50%-27.16%-60.75%OCSOculis-0.35%+6.44%-5.60%-12.43%+43.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.64+7.0%$3.43$2.70▼$4.62$891.40M1.01910,144 shs1.42 million shsCGTXCognition Therapeutics$2.49-1.6%$1.32$0.22▼$3.83$184.54M1.334.89 million shs1.82 million shsNRIXNurix Therapeutics$9.00-2.2%$10.87$8.18▼$29.56$689.57M2.1859,324 shs247,228 shsOCSOculis$17.15-0.2%$17.77$11.78▼$23.08$748.77M0.2642,405 shs12,823 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+5.87%+13.35%+27.35%+23.71%-3.56%CGTXCognition Therapeutics+5.42%+4.12%+235.32%+697.60%+318.53%NRIXNurix Therapeutics-5.15%+0.99%-6.50%-27.16%-60.75%OCSOculis-0.35%+6.44%-5.60%-12.43%+43.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.007.87% UpsideCGTXCognition Therapeutics 3.25Buy$2.8313.79% UpsideNRIXNurix Therapeutics 2.88Moderate Buy$29.07223.09% UpsideOCSOculis 3.00Buy$35.75108.45% UpsideCurrent Analyst Ratings BreakdownLatest CGTX, NRIX, ABUS, and OCS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025OCSOculisNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.008/26/2025NRIXNurix TherapeuticsBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/22/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $33.008/11/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.007/31/2025NRIXNurix TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$32.00 ➝ $30.007/15/2025NRIXNurix TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$17.00 ➝ $16.007/14/2025NRIXNurix TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $34.007/10/2025NRIXNurix TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $26.007/10/2025NRIXNurix TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$32.00 ➝ $30.007/10/2025NRIXNurix TherapeuticsStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$30.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$15.42M57.64N/AN/A$0.51 per share9.09CGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/ANRIXNurix Therapeutics$88.38M7.78N/AN/A$7.44 per share1.21OCSOculis$780K959.96N/AN/A$1.91 per share8.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.29N/AN/AN/A-352.24%-59.28%-44.11%11/5/2025 (Estimated)CGTXCognition Therapeutics-$33.97M-$0.67N/AN/AN/AN/A-251.23%-130.75%11/12/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.61N/AN/AN/A-234.57%-45.26%-34.71%10/10/2025 (Estimated)OCSOculis-$97.43M-$2.67N/AN/AN/A-13,958.12%-90.31%-67.85%11/6/2025 (Estimated)Latest CGTX, NRIX, ABUS, and OCS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025OCSOculis-$0.53-$0.59-$0.06-$0.59$0.14 million$0.25 million8/7/2025Q2 2025CGTXCognition Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/A8/6/2025Q2 2025ABUSArbutus Biopharma-$0.02$0.01+$0.03$0.01$2.21 million$10.74 million7/9/2025Q2 2025NRIXNurix Therapeutics-$0.79-$0.52+$0.27-$0.52$16.26 million$44.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A20.5320.53CGTXCognition TherapeuticsN/A1.541.54NRIXNurix TherapeuticsN/A6.826.82OCSOculis0.014.554.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%CGTXCognition Therapeutics43.35%NRIXNurix TherapeuticsN/AOCSOculis22.30%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%CGTXCognition Therapeutics14.40%NRIXNurix Therapeutics7.40%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.70 million152.78 millionOptionableCGTXCognition Therapeutics2073.52 million62.94 millionNot OptionableNRIXNurix Therapeutics30076.45 million70.79 millionOptionableOCSOculis243.66 millionN/ANot OptionableCGTX, NRIX, ABUS, and OCS HeadlinesRecent News About These CompaniesOCS-01 eye drop for DME performs equally well in phakic, pseudophakic eyesSeptember 9 at 11:42 PM | healio.comHOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesSeptember 9 at 4:05 PM | globenewswire.com131,332 Shares in Oculis Holding AG $OCS Acquired by Alyeska Investment Group L.P.September 8 at 5:14 AM | marketbeat.comOculis (NASDAQ:OCS) Sees Large Volume Increase - What's Next?September 5, 2025 | marketbeat.comOculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short InterestSeptember 5, 2025 | marketbeat.comOculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025September 4, 2025 | globenewswire.comOculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025September 4, 2025 | globenewswire.comOculis Holding AG to Present Phase 2 ACUITY Trial Results for Privosegtor and Expanded Phase 3 DIAMOND Data at EURETINA CongressSeptember 1, 2025 | quiverquant.comQOculis Holding AG to Present Phase 2 and Phase 3 Clinical Trial Results at EURETINA and Other Key Ophthalmology ConferencesSeptember 1, 2025 | quiverquant.comQOculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology ConferencesSeptember 1, 2025 | globenewswire.comOculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology ConferencesSeptember 1, 2025 | globenewswire.comOculis (NASDAQ:OCS) Coverage Initiated at Needham & Company LLCAugust 29, 2025 | marketbeat.comOculis Holding AG Management to Participate in September Investor ConferencesAugust 28, 2025 | quiverquant.comQOculis Holding AG to Participate in Notable Investor Conferences in September 2025August 28, 2025 | quiverquant.comQOculis to Participate in Upcoming September Investor ConferencesAugust 28, 2025 | globenewswire.comOculis to Participate in Upcoming September Investor ConferencesAugust 28, 2025 | globenewswire.comOculis initiated with a Buy at NeedhamAugust 27, 2025 | msn.comOculis Holding AG $OCS Shares Bought by Pivotal bioVenture Partners Investment Advisor LLCAugust 26, 2025 | marketbeat.comOculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors in Neuro-Ophthalmology and Ophthalmology RespectivelyAugust 25, 2025 | quiverquant.comQOculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors to Lead Advances in Neuro-Ophthalmology and OphthalmologyAugust 25, 2025 | quiverquant.comQOculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.August 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGTX, NRIX, ABUS, and OCS Company DescriptionsArbutus Biopharma NASDAQ:ABUS$4.64 +0.31 (+7.04%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Cognition Therapeutics NASDAQ:CGTX$2.49 -0.04 (-1.58%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Nurix Therapeutics NASDAQ:NRIX$9.00 -0.20 (-2.20%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Oculis NASDAQ:OCS$17.15 -0.04 (-0.23%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
